nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

26.12.2017 | Editorial Commentary

Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction

verfasst von: Felix M. Mottaghy

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Excerpt

Several combinations of hybrid imaging have been evaluated in the last two decades [1]. From the beginning, it was clear that the combination of nuclear molecular imaging by means of PET or SPECT combined with contrast-enhanced computed tomography added a significant aspect on the sensitivity and specificity as well as the accuracy of the combined integrated methods compared to the side-by-side reading [2, 3]. …

de Galiza BF, Delso G, Ter Voert EE, Huellner MW, Herrmann K, Veit-Haibach P. Multi-technique hybrid imaging in PET/CT and PET/MR: What does the future hold? Clin Radiol. 2016;71:660–72. https://doi.org/10.1016/j.crad.2016.03.013.CrossRef

Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–803.PubMed

Mottaghy FM, Sunderkotter C, Schubert R, Wohlfart P, Blumstein NM, Neumaier B, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging. 2007;34:1355–64. https://doi.org/10.1007/s00259-006-0358-1.CrossRefPubMed

Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–5.PubMed

Kuhl DE, Phelps ME, Hoffman EJ, Robinson GD Jr, MacDonald NS. Initial clinical experience with 18F-2-fluoro-2-deoxy-d-glucose for determination of local cerebral glucose utilization by emission computed tomography. Acta Neurol Scand Suppl. 1977;64:192–3.PubMed

Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose. Acta Neurol Scand Suppl. 1977;64:190–1.PubMed

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122s–50s. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMedPubMedCentral

Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: From daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2.CrossRefPubMedPubMedCentral

Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: Updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55–66. https://doi.org/10.1007/s00259-017-3687-3.CrossRefPubMed

10.

Kim JH. Comparison of the EORTC criteria and PERCIST in solid tumors: A pooled analysis and review. Oncotarget. 2016;7:58105–10. https://doi.org/10.18632/oncotarget.11171.PubMedPubMedCentral

11.

JH O, Lodge MA, Wahl RL. Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280:576–84. https://doi.org/10.1148/radiol.2016142043.CrossRef

12.

Min SJ, Jang HJ, Kim JH. Comparison of the RECIST and PERCIST criteria in solid tumors: A pooled analysis and review. Oncotarget. 2016;7:27848–54. https://doi.org/10.18632/oncotarget.8425.PubMedPubMedCentral

13.

Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med. 1989;15:61–6.CrossRefPubMed

14.

Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1991;179:765–70. https://doi.org/10.1148/radiology.179.3.2027989.CrossRefPubMed

15.

Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J. 2010;16:617–24. https://doi.org/10.1111/j.1524-4741.2010.00987.x.CrossRefPubMed

16.

Goorts B, Voo S, van Nijnatten TJA, Kooreman LFS, de Boer M, Keymeulen K, et al. Hybrid (18)F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3745-x.

17.

van Nijnatten TJA, Goorts B, Voo S, de Boer M, Kooreman LFS, Heuts EM, et al. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: A feasibility study. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3823-0.

18.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676–88. https://doi.org/10.1200/JCO.2000.18.8.1676.CrossRefPubMed

19.

Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144–50.PubMed

20.

Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, et al. The prognostic impact of early change in 18F-FDG PET SUV after neoadjuvant chemotherapy in patients with locally advanced breast cancer. J Nucl Med. 2016;57:1183–8. https://doi.org/10.2967/jnumed.115.166322.CrossRefPubMed

21.

Dietzel M, Kaiser C, Pinker K, Wenkel E, Hammon M, Uder M, et al. Automated semi-quantitative analysis of breast MRI: Potential imaging biomarker for the prediction of tissue response to neoadjuvant chemotherapy. Breast Care (Basel). 2017;12:231–6. https://doi.org/10.1159/000480226.CrossRef

22.

Bufi E, Belli P, Di Matteo M, Giuliani M, Tumino M, Rinaldi P, et al. Hypervascularity predicts complete pathologic response to chemotherapy and late outcomes in breast cancer. Clin Breast Cancer. 2016;16:e193–201. https://doi.org/10.1016/j.clbc.2016.06.007.CrossRefPubMed

23.

Michoux N, Van den Broeck S, Lacoste L, Fellah L, Galant C, Berliere M, et al. Texture analysis on MR images helps predicting non-response to NAC in breast cancer. BMC Cancer. 2015;15:574. https://doi.org/10.1186/s12885-015-1563-8.CrossRefPubMedPubMedCentral

24.

Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, et al. Effect of imaging parameter thresholds on MRI prediction of neoadjuvant chemotherapy response in breast cancer subtypes. PLoS One. 2016;11:e0142047. https://doi.org/10.1371/journal.pone.0142047.CrossRefPubMedPubMedCentral

25.

von Minckwitz G, Blohmer JU, Costa SD, Denkert C, Eidtmann H, Eiermann W, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31:3623–30. https://doi.org/10.1200/JCO.2012.45.0940.CrossRef

26.

Leijenaar RT, Carvalho S, Velazquez ER, van Elmpt WJ, Parmar C, Hoekstra OS, et al. Stability of FDG-PET radiomics features: An integrated analysis of test-retest and inter-observer variability. Acta Oncol. 2013;52:1391–7. https://doi.org/10.3109/0284186X.2013.812798.CrossRefPubMed

27.

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: The bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62. https://doi.org/10.1038/nrclinonc.2017.141.CrossRefPubMed

28.

Margolies LR, Pandey G, Horowitz ER, Mendelson DS. Breast imaging in the era of big data: Structured reporting and data mining. AJR Am J Roentgenol. 2016;206:259–64. https://doi.org/10.2214/AJR.15.15396.CrossRefPubMed

29.

Cho N, Im SA, Cheon GJ, Park IA, Lee KH, Kim TY, et al. Integrated (18)F-FDG PET/MRI in breast cancer: Early prediction of response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3849-3.

30.

Jena A, Taneja S, Singh A, Negi P, Mehta SB, Ahuja A, et al. Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer. Eur J Radiol. 2017;92:30–6. https://doi.org/10.1016/j.ejrad.2017.04.013.CrossRefPubMed

31.

Groheux D, Mankoff D, Espie M, Hindie E. (1)(8)F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: Review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging. 2016;43:983–93. https://doi.org/10.1007/s00259-015-3295-z.CrossRefPubMed

32.

Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: A guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging. 2017;44:41–54. https://doi.org/10.1007/s00259-017-3695-3.CrossRefPubMedPubMedCentral

Titel: Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction
verfasst von: Felix M. Mottaghy
Publikationsdatum: 26.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3908-9

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction

Excerpt

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status

Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia

Clinical utility of FDG PET/CT in acute complicated pyelonephritis—results from an observational study

Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma

Striking lack of visualization of striatum on 18F-FDG brain PET in chorea-acanthocytosis

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review